China prostate cancer diagnostic and therapeutic market was valued at $2,276.9 million in 2025 and is projected to reach $5,906.0 million by 2035, growing at a CAGR of 10.0% during the forecast period (2026-2035). Rapid innovation in prostate cancer diagnostics and therapeutics is reshaping the China market by broadening clinical options, improving diagnostic accuracy, and supporting earlier, more actionable disease detection. Recent efforts within China’s oncology ecosystem are accelerating development of advanced tools including AI-assisted imaging platforms and novel therapeutic agents that help clinicians detect and characterize prostate tumors more reliably and tailor treatment based on individual patient biology. Collaborative AI diagnostic models using federated learning frameworks have achieved very high discriminatory performance across multi-hospital datasets, showing potential to improve early detection and reduce diagnostic variability across regions.
Browse the full report description of “China Prostate Cancer Diagnosis & Treatment Market Size, Share & Trends Analysis Report by Diagnostic Technique (Prostate Specific Antigen Test, Digital Rectal Exam), by Therapy (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy) Forecast Period, 2026–2035” at https://www.omrglobal.com/industry-reports/china-prostate-cancer-diagnostic-therapeutic-market
Therapeutic innovation is also driving material expansion of the market by introducing new classes of targeted treatments and radiopharmaceuticals that extend clinical utility beyond conventional hormone therapy and chemotherapy. For instance, in 2026, China’s Centre for Drug Evaluation approved the clinical trial application for a ^177Lu-PSMA-I&T radioligand therapy intended for patients with metastatic, treatment-resistant prostate cancer, marking a step forward in the development of targeted radionuclide treatment options within the country. This type of precision therapy represents an emerging treatment segment that can command higher per-patient revenue and extend treatment durations, while meeting critical unmet needs in advanced disease stages. Adoption of such therapies typically goes hand in hand with investments in specialized infrastructure, training, and referral networks, further increasing utilization of companion diagnostics and advanced imaging.
Key Leaders Transforming the China Prostate Cancer Diagnostic and Therapeutic Market
The key players in the China prostate cancer diagnostic and therapeutic market include Astellas Pharma Inc., F. Hoffmann-La Roche AG, Pfizer Inc., Johnson & Johnson Services, Inc., Bayer AG, among others. These companies are driving innovation in the prostate cancer market through the development of next-generation immunotherapies, PSMA-targeted radiopharmaceuticals, precision imaging agents, and advanced molecular diagnostic platforms. Their focus on improving treatment efficacy, enhancing safety profiles, enabling earlier and more accurate detection, and supporting personalized therapy approaches is accelerating progress in advanced and metastatic prostate cancer care across global healthcare markets.
Market Coverage
Key questions addressed by the report.
China Prostate Cancer Diagnostic and Therapeutic Market Report Segment
By Diagnostic Technique
By Therapeutics
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/china-prostate-cancer-diagnostic-therapeutic-market